Xeris director sells 10,834 shares under plan

Xeris Biopharma Holdings director Brady James Aloysius sold 10,834 shares of common stock in an open-market transaction.

Rhea-AI Filing Summary

Xeris Biopharma Holdings director Brady James Aloysius sold 10,834 shares of common stock in an open-market transaction. The shares were sold at a weighted average price of $5.5414 per share under a Rule 10b5-1 trading plan. Following the sale, he directly holds 89,166 shares. The sale price reflects multiple trades in a range from $5.29 to $5.63 per share.

Insider Trade Summary 10b5-1

Net Seller: 10,834 shares

Net Sell 1 txn

Insider Brady James Aloysius

Role Director

Sold 10,834 shs ($60K)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,834	$5.5414	$60K

Holdings After Transaction: Common Stock — 89,166 shares (Direct)

Footnotes (2)

1. F1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
2. F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.290 to $5.630, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Shares sold: 10,834 shares Weighted average sale price: $5.5414 per share Price range of sales: $5.29 to $5.63 per share +1 more

4 metrics

Shares sold 10,834 shares Open-market sale on 2026-03-30

Weighted average sale price $5.5414 per share Common stock sale

Price range of sales $5.29 to $5.63 per share Multiple transactions within the sale

Shares owned after transaction 89,166 shares Direct ownership following sale

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did XERS director Brady James Aloysius do in this Form 4 filing?

Brady James Aloysius reported selling 10,834 shares of Xeris Biopharma Holdings common stock. The transaction was an open-market sale executed under a pre-established Rule 10b5-1 trading plan, meaning the trades were scheduled in advance rather than timed discretionarily.

At what price did Brady James Aloysius sell XERS shares?

He sold the 10,834 Xeris Biopharma Holdings shares at a weighted average price of $5.5414. Individual trades occurred in multiple transactions, with prices ranging from $5.29 to $5.63 per share, according to the weighted average pricing footnote in the filing.

How many XERS shares does Brady James Aloysius own after this transaction?

After the reported sale, Brady James Aloysius directly owns 89,166 shares of Xeris Biopharma Holdings common stock. This post-transaction holding figure comes directly from the Form 4 and reflects his remaining direct ownership following the 10,834-share disposition.

Was the XERS insider sale made under a Rule 10b5-1 trading plan?

Yes, the filing states the sale was effected under a Rule 10b5-1 trading plan adopted by the reporting person. Such plans pre-schedule trades, helping separate routine portfolio management from discretionary timing decisions based on short-term market conditions.

What does the weighted average price disclosure mean in the XERS Form 4?

The Form 4 reports a weighted average sale price of $5.5414 for the 10,834 shares. A footnote explains the shares were sold in multiple trades between $5.29 and $5.63, and detailed per-trade pricing is available from the reporting person upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/01/2026 - 05:54 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brady James Aloysius

(Last) (First) (Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO ILLINOIS 60607

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/30/2026		S(1)		10,834	D	$5.5414(2)	89,166	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.290 to $5.630, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

	/s/ Beth Hecht, Attorney-in-Fact	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)